Arvinas enters into a transaction with Novartis, including a Global License Agreement for the development and commercialization of ARV-766
Arvinas, a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has entered into an exclusive strategic license agreement with Novartis for the worldwide development and commercialization of ARV-766, Arvinas’ second generation…